ALS Limited Falls Despite Record FY26 Profit
ALS Limited (ASX: ALQ) shares slipped 1.7% on Monday to close at A$21.83, even after the lab testing giant reported the strongest year in its history. Revenue climbed 10.7% to A$3.32 billion and underlying profit jumped 25.8% to A$381.2 million, with the company also paying down debt. So why didn’t the market cheer? In our view, the result was already in the price. ALS shares are up about 25% over the past year and trade on a fairly demanding earnings multiple, so anything less than perfection was always going to disappoint. Management’s outlook for FY27, while still healthy, points to slower growth ahead, and that is what investors are reacting to.
What are the Best ASX Stocks to invest in right now?
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
ALS Cashes In on the Mining Boom
The Commodities division did the heavy lifting, with divisional revenue of A$1.29 billion, up 18.8% on the back of stronger mineral exploration activity. With gold near record highs and copper at multi-year peaks, exploration activity has been strong, and ALS quietly takes a cut of every sample that comes through the door. Life Sciences grew a steady 6%, helped by its food business, while Environmental was softer in the Americas, where management says it is working through some internal and market issues.
We see ALS Limited as one of the cleanest ways to play the commodities cycle without owning miners. They take the production and price risk; ALS just earns a steady fee for testing the rocks. The catch is that when exploration slows, so does ALS, which is why the market is careful not to get too excited even in a strong year.
Why the Market Sold the Beat
The selloff comes down to three things. First, FY27 growth guidance is a clear step down from this year, and growth-focused investors tend to head for the exit at the first sign of cooling momentum. Second, the soft patch in the Americas adds a small wrinkle to an otherwise clean result. Third, the stock simply wasn’t priced for anything less than a flawless update.
We believe the positives are being overlooked. The balance sheet is in better shape than management’s own target, which gives plenty of room for acquisitions or buybacks. New labs in Sydney and Lima are also set to come online late next year, adding capacity just as the cycle should still be running. The intraday tape told its own story: shares spiked above A$22.90 in early trade before fading through the afternoon as investors digested the slower FY27 outlook. That is a profit-taking signature, not a vote of no confidence.
The Investor’s Takeaway for ALS Limited
ALS Limited is not cheap, but a track record of steady growth, expanding margins and improving debt levels makes a case for paying up for quality. The bull case is more of the same. The bear case is mining exploration cooling off, and the multiple drifting lower.
For long-term holders, nothing about today’s drop breaks the thesis. For new buyers, a slightly deeper pullback would likely offer a better entry point. Income investors get confirmation that the dividend is well covered, but with a yield under 2%, dividends are not the reason to own this stock. ALS Limited is a quality compounder, not an income play.
